TY - JOUR
T1 - Erratum
T2 - PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors (Oncotarget (2019) 10 (5755-5767) DOI: 10.18632/oncotarget.27206)
AU - Smith, Amanda M.
AU - Zhang, Christine R.C.
AU - Cristino, Alexandre S.
AU - Grady, John P.
AU - Lynn Fink, J.
AU - Moore, Andrew S.
N1 - Publisher Copyright:
© Smith et al.
PY - 2020/1/21
Y1 - 2020/1/21
N2 - This article has been corrected: During production, the 4th affiliation was mistakenly added to the name of the last author, Dr. Andrew S. Moore. The proper affiliation information is shown below. Original article: Oncotarget. 2019; 10:5755-5767. https://doi.org/10.18632/oncotarget.27206. Amanda M. Smith1,4,*, Christine R.C. Zhang1,4,*, Alexandre S. Cristino1,6, John P. Grady1,5, J. Lynn Fink1 and Andrew S. Moore1,2,3. 1The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia. 2Oncology Services Group, Queensland Children’s Hospital, South Brisbane, Australia. 3 Child Health Research Centre, The University of Queensland, South Brisbane, Australia. 4Current address: Washington University in Saint Louis, Saint Louis, Missouri, United States of America. 5Current address: Garvan Institute of Medical Research, Darlinghurst, Australia. 6Current address: Griffith Institute for Drug Discovery, Brisbane Innovation Park, Nathan, Australia. *These authors contributed equally to this work.
AB - This article has been corrected: During production, the 4th affiliation was mistakenly added to the name of the last author, Dr. Andrew S. Moore. The proper affiliation information is shown below. Original article: Oncotarget. 2019; 10:5755-5767. https://doi.org/10.18632/oncotarget.27206. Amanda M. Smith1,4,*, Christine R.C. Zhang1,4,*, Alexandre S. Cristino1,6, John P. Grady1,5, J. Lynn Fink1 and Andrew S. Moore1,2,3. 1The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia. 2Oncology Services Group, Queensland Children’s Hospital, South Brisbane, Australia. 3 Child Health Research Centre, The University of Queensland, South Brisbane, Australia. 4Current address: Washington University in Saint Louis, Saint Louis, Missouri, United States of America. 5Current address: Garvan Institute of Medical Research, Darlinghurst, Australia. 6Current address: Griffith Institute for Drug Discovery, Brisbane Innovation Park, Nathan, Australia. *These authors contributed equally to this work.
UR - http://www.scopus.com/inward/record.url?scp=85078988396&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.27402
DO - 10.18632/oncotarget.27402
M3 - Comment/debate
C2 - 32076493
AN - SCOPUS:85078988396
SN - 1949-2553
VL - 11
SP - 305
JO - Oncotarget
JF - Oncotarget
IS - 3
ER -